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The interaction of IL-2 with the IL-2-R plays a central role in the regulation of
T lymphocyte proliferation (1) . Triggering oftheTCR leads to the synthesis of IL-2
(in certainT lymphocyte subsets) and to the induction of high affinity IL-2-Rs in
antigen-activated T lymphocytes (2-4) . It is the binding of IL-2 to the high affinity
IL-2-R (and the subsequent internalization of this complex) that leads to the cas-
cade of events resulting in T lymphocyte proliferation (5, 6) .
While the role of IL-2/IL-2-R interaction in drivingT lymphocytes into the cell
cycle is well established, the factors that control the magnitude and duration of T
lymphocyte proliferation in response to antigen are less well understood . Early evi-
dence favored the view that IL-2 availability was the sole regulator ofT lymphocyte
proliferation (1, 4) . Later studies on the kinetics of IL-2-R expression revealed that
IL-2-Rs were only transiently expressed on activated T lymphocytes and that the
level of cell surface IL-2-Rs declined as a function of time after activation (7, 8) .
This evidence suggested a second site ofhormonal control ofT lymphocyte prolifer-
ation, i.e ., level of expression of the hormone (IL-2) receptor. Accordingly, antigen
would then serve to triggerTlymphocyte expansion by engaging theTCRon quies-
centT lymphocytes and thereby stimulate a burst of IL-2-R expression . More re-
cently, athird possible site for the regulation ofTlymphocyte proliferation has been
suggested from ourobservations on the time course of high affinity IL-2-R expres-
sion in antigen-regulated murine T lymphocyte clones . This analysis revealed that
T lymphocytes that have undergone a cycle of antigen-driven proliferation (6-10 di-
visions) were refractory to the proliferative stimulus of IL-2 in spite of high levels
of high affinity IL-2-Rs (9) . The high affinity IL-2-Rs on these quiescent refractory
T lymphocytes are functional by several criteria, e.g ., internalization of IL-2/1L-2-R
complexes, upregulation of expression of the IL-2-R p55 gene, and protein expres-
sion. Engagement of theT lymphocyte antigen receptor on these quiescentTlym-
phocytes rapidly rendered the cells sensitive to the proliferative stimulus of IL-2 (9,
10) . These findings implied that an intracellular regulator (or family of regulators)
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in T lymphocytes may also play a central role in the control of T lymphocyte activa-
tion/proliferation.
In this report we have examined the expression of a panel of genes in T lympho-
cyte clones during the IL-2-sensitive (activated) and IL-2-insensitive (quiescent) phase
oftheir activation cycle. We have found that the c-myb gene is transcribed as a result
of the IL-2/IL-2-R interaction in activated (day 1-3 after antigenic stimulation) but
not quiescent (day 9-14 after stimulation) T lymphocytes. Therefore, the expression
ofthe proto-oncogene c-myb directly correlates with the state of activation ofT lym-
phocytes and the sensitivity of these cells to the IL-2-driven proliferative stimulus.
The role of c-myb as a critical regulator of proliferation was confirmed in studies
with c-myb antisense oligodeoxynucleotide. We also provide evidence for the exis-
tence ofdistinct IL-2-R-dependent and TCRdependent pathways of c-myb expression.
Materials and Methods
Mice.
￿
(BALB/cj x C57B6/6J)F, (H-2`' x H-26
) (CB6F,) mice were purchased from The
Jackson Laboratory, Bar Harbor, ME.
Viruses.
￿
Influenza virus strain A/JAPAN/305/57 (H2N2) was grown in the allantoic cavi-
ties of 10-d-old chick embryos. Infectious allantoic fluid was harvested 2 d later, aliquoted,
and stored at -70'C.
T Lymphocyte Clones.
￿
The murine T lymphocyte clones were established as described in
detail elsewhere (11) . Briefly, the clones used in this study were derived from the spleen of
A/JAP/57 influenza virus-immune CB6F, mice by limiting dilution in the presence of an-
tigen (irradiated, A/JAP/57-infected, syngeneic spleen cells), plus a source ofIL-2 (superna-
tant from Con A-stimulated rat spleen cells) in Iscove's modified Dulbeccds medium (Gibco
Laboratories, Grand Island, NY), plus 10% FCS (Sterile Systems, Logan, UT). The clones
were subsequently maintained by weekly passage in the presence of antigen plus rat Con
A supernatant.
Cellular Proliferation Assay.
￿
The proliferative response was estimated by the incorporation
of ['H]TdR, as described (12).
Radiolabeled IL-2 Binding Assay.
￿
Radiolabeled IL-2 binding to intact cells was performed
essentially as previously described (9). Cells were first separated from debris by centrifuga-
tion over a Metrizoate/Ficoll gradient, followed by incubation at 37°C for two 1-h periods
in RPMI 1640 with extensive washes between incubations to facilitate removal or degrada-
tion of bound IL-2. Serial dilutions of 1251-labeled human rIL-2 (New England Nuclear,
Boston, MA) were incubated with 2-8 x 105 cells in binding buffer (RPMI 1640, 25 nM
Hepes, 10 mg/ml BSA, 0.1% NaN3) for 15 min in a total volume of 100 wl. After 15 min,
1 ml of cold binding buffer was added and the cells were centrifuged at 9,000 g for 20 s in
a microfuge. The supernatant was then removed and counted. The cells were washed with
an additional 1 ml, then resuspended in 100 1A1 of binding buffer, underlayed with 200 A1
of a 2 :5 mixture of Metrizoate/Ficoll to binding buffer, and centrifuged for 90 s at 9,000 g.
The tips of the tubes containing the cell pellet were cut off and counted in a gamma counter.
Nonsaturable binding was determined by inclusion of a 150-fold molar excess of unlabeled
human rIL-2 (kindly provided by Drs. Bruce Devins and David Webb, Roche Institute of
Molecular Biology, Nutley, NJ).
Northern Blots.
￿
Total RNA was prepared according to the method of Chirgwin et al. .~13).
For Northern blot hybridization, 10-15 kg of RNA from each sample was heated at 65°C
in 50% formamide/6.6% formaldehyde in 4-morpholine-propane sulfonic acid (MOPS) buffer
and subjected to electrophoresis in a 0.8% agarose gel containing 6.6% formaldehyde. After
electrophoresis, the RNA was transferred to Magnagraph nylon hybridization paper (MSI
Micron Separations Inc., Westboro, MA) . Hybridization was carried out at 42'C for 18 h
with probes containing radioactivity of 2-5 x 10' cpm . Blots were washed three times in 2 x
SSC, 0 .1% SDS at ambient temperature for 15 min each wash and two times in 0.2 x SSC,CHURILLA ET AL.
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0.1% SDS at 56°C for 15 min each wash. Blots were exposed to Kodak XAR film at -70°C
for 2-3 d.
DNA Probes.
￿
All probes utilized in this study were purified inserts isolated after restric-
tion enzyme digestion, electrophoresis in 1% agarose, and extraction by electroelution. The
v-fms probewas a 1.5-kb fragment of v-fms cDNA provided by Dr. Jeff Milbrandt (Washington
University, St. Louis, MO). The p53 probe was a 745-bp fragment excised from a cDNA
clone ofmouse p53 provided by Dr. A. Bernstein (Mount Sinai Hospital Research Institute,
Toronto, Ontario, Canada). C-myb was a 500-bp fragment from a mouse cDNA clone provided
by Dr. G. Shen-Ong (National Cancer Institute, Bethesda, MD). C-myc was a 1.8-kb frag-
ment of a cDNA clone to mouse c-myc provided by Dr. M. Cole (Princeton University,
Princeton, NJ). The probe for lck was a 1,750-bp fragment of a cDNA clone to mouse lck
provided by Dr. R. Perlmutter (University of Washington, Seattle, WA). c-abl was a 4.4-bp
fragment of a cDNA clone to mouse c-abl provided by Dr. A. Bernards and Dr. D. Baltimore
(Whitehead Institute for Biomedical Research, Cambridge, MA). The MHC (Kd) gene
probe was a 852-bp fragment of a cDNA clone to the mouse Kd gene provided by P. Kouril-
sky (Pasteur Institute, Paris, France).
Antisense Oligodeoxynucleolide Inhibition.
￿
Antisense oligodeoxynucleotides complementary
to the Tend ofthe mRNA coding for mouse c-myb and c-myc were synthesized on a multiple
column DNA synthesizer. The choice of sites for these complementary sequences was based
on published observations (14, 15). Cells (6 d after antigenic stimulation) were pre-incubated
at 4 x 105 cells/well for 2 h in AIMV, serum-free medium (Gibco Laboratories, Grand Is-
land, NY) alone or with c-myb antisense oligodeoxynucleotide (5'-GGGTCTCCGGGCCAT3'),
c-myc antisense oligodeoxynucleotide (5'-CACGTTGAGGGGCAT3'), or a scrambled c-myb
nonsense oligodeoxynucleotide(5'-CTGCAGTGGCCTGCG-3') at 30 gM. After 2 h the cells
were subcultured into 96-well plates at 4 x 104 cells/well with 50 pM human rIL-2 for 24 h,
then pulsed for 6 h with 1 p.Ci [3H]TdR/well. The cultures were harvested onto glass fiber
filters and counted by liquid scintillation. In analyses of the dose dependence of c-myb anti-
sense oligodeoxynucleotide inhibition, significant specific inhibition was observed at oligodeoxy-
nucleotide concentrations as low as 2.4 j.M and optimum inhibition was demonstrable at con-
centrations ranging from 10 to 50 juM.
Anti-7UR Stimulation.
￿
Cells were stimulated with antiTCR mAb as previously described
(16). Briefly, tissue culture plates (6-well plates for subsequent Northern analysis or 96-well
plates for proliferation assay) were treated with 8 p,g/ml rat anti-mouse Ig (Jackson Im-
munoresearch Laboratories, Inc., West Grove, PA) at 37°C overnight. The plates were then
washed with media to remove unbound antibodies and incubated with a 1 :10 dilution of F23.1
hybridoma supernatant for 1 h at 37°C. After washing off unbound F23.1 antibody, cloned
T lymphocytes were added and incubated at 37°C.
After incubating the cells in F23-coated plates, cells for Northern analysis were resuspended,
washed twice with media, and theirtotal RNA was extracted (13). Cells in F23-coated 96-well
plates for analysis of proliferation were pulsed for 6 h with 1 uCi/well [3H]TdR.
Results
Transcriptional Expression of the Proto-oncogenes p53, lck, c-abl, c:/ms, c-myc, and c-myb
in TLymphocyte Clones with Time afterAntigenic Stimulation. We previouslyreported (9)
that antigen-driven cytolytic T lymphocyte clones proliferate vigorously in response
to IL-2 early after antigenic stimulation (days 1-3). Late (days 5-8) after stimula-
tion, the clones' responsiveness to the IL-2-proliferative stimulus wanes, and this
unresponsiveness is associated with a 10-50-fold drop in the expression ofthe IL-2-R
p55 protein (3). Despite this, relatively high levels of high affinity IL-2-R remain
on these quiescent cells (9). Table I shows the IL-2-R sites per cell and the prolifera-
tive response ofthree influenza-specific, class I MHC-restricted cytolytic T lympho-
cyte clones at day 3 and days 10-14 after antigenic stimulation. Early after antigenic108
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TABLE I
Proliferative Response of Three Influenza-specific, Class I MHC-restricted
Cytolytic T Lymphocyte Clones
"' IL-2 binding analysis was conducted as discussed previously (9).
1 Cells (at early and late times after antigenic stimulation) were incubated in 96-well plates
at 104 cells/well for 48 h in media alone or in 500 pM human rIL-2. Values are the mean
cpm ± SEM of quadruplicate cultures after a 4-h pulse with 1 ,ACi [3H]TdR/well.
stimulation the cells vigorously proliferate in response to IL-2 . However, by day 10
after stimulation, little proliferation is evident, even though these cellshave 42-69%
of the level of high affinity IL-2-R as seen early after antigenic stimulation. Although
unable to transmit a proliferative signal, the high affinity IL-2-Rs on these quiescent
cells are functional by several criteria (9 ; and see below).
Since the high affinity IL-2-Rs were still capable of signal transduction late after
antigenic stimulation, we reasoned that an essential regulatory element necessary
for movement of the T cells into S phase may not be expressed (or activated) as
a result of the IL-2/IL-2-R interaction in these quiescent cells. Since a number of
cellular proto-oncogenes have been implicated as important regulators of lympho-
cyte growth (17), we considered the possibility that the unresponsiveness of the T
cellsto IL-2 late after antigenic stimulation might be linked to a block of expression
of one or more of these cellular proto-oncogenes. To investigate this hypothesis we
screened a panel of clones for transcriptional expression ofa number ofproto-oncogenes
at day 3 after antigenic stimulation, when they proliferate vigorously to IL-2, and
day 10-14 after stimulation, when they are refractory to the proliferative stimulus
of IL-2. The proto-oncogenes selected (c-abl, c-fins, lck, p53, c-myc, and c-myb) have
been previously implicated in the regulation of lymphocyte growth and activation
(18-25). Total RNA was extracted from T lymphocyte clones at the early and late
time points and examined by Northern analysis. As shown in Fig. 1, transcription
of the proto-oncogenes c-abl, cfms, lck, and p53 in clones 14-13 and 14-7 was com-
parable at early and late times. The continued high level expression of these genes
late after activation suggests that although these genes may be necessary for cellular
proliferation, they may not be playing a critical regulatory role in the IL-2/IL-2-R
signal in quiescent clones leading to progression through the cell cycle. C-myc tran-
scripts are also readily detectable at day 3 in both 14-13 and 14-7 . At the late time
point (day 10-12), c-mycexpression is detectable in both clones but at reduced levels,
as is evident in clone 14-7 at day 12 after stimulation. On the other hand, the c-myb
proto-oncogene was expressed at day 3 after activation but was not detectable late
Day
Clone
after antigenic
stimulation High affinity IL-2-R'
[3H]TdR
Media
incorporationi
500 pM IL-2
siles/cell cpm
14-13 3 6,300 47 ± 20 185,586 t 14,372
10 4,350 70 ± 20 4,633 t 206
11-1 3 5,952 447 ± 49 191,193 f 12,146
10 2,550 400 t 26 3,064 t 197
14-7 3 5,100 103 ± 14 215,588 ± 10,697
14 2,326 94 t 51 1,054 t 89CHURILLA ET AL .
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FIGURE 1 .
￿
Proto-oncogene transcriptional expression at early and late times after antigenic stim-
ulation of class I MHC-restricted cytolyticT lymphocyte clones 14-13 (A) and 14-7 (B) . Total
RNA was extracted from cells early and late after antigenic stimulation, and the expression of
various proto-oncogenes was assessed by Northern analysis .
afteractivation . The low level ofc-myc and the undetectable level of c-myb transcrip-
tional expression in both clones late after antigenic stimulationraised the possibility
that expression of one or both of these nuclear proto-oncogenes might be causally
related to the IL-2-driven proliferative stimulus .
The Expression of the Proto-oncogenes c-myc and c-myb, in Response to IL-2 in Early
and Late Activated T Lymphocytes . One explanation for the low expression of
c-myc and c-myb transcripts late after activation was that the exogenous IL-2 in the
late culturehad been exhausted . We tested this by subculturing quiescent(day 10-14)
T lymphocyte clones in a supraoptimal concentration ofHL-2 (500 pM) and then
examined expression of the c-myc and c-myb genes at various times after IL-2 ex-
posure . To verify theimpact ofIL-2 on c-myc and c-mybexpression in activatedclones,
we exposed cells taken day 3 after antigenic stimulation to an identical regimen of
subculture in 500 pM HL-2 . As shown in Fig . 2 for three T lymphocyte clones,
expression of the c-myc gene markedly unregulated in activated (day 3) clones after
exposure to IL-2 with maximal expression demonstrable at -4 h. Surprisingly, in
quiescent clones (day 10-14), c-myc was inducible to virtually the same level seen
in activated cells in spite of the absence of significant IL-2-dependent proliferation
in these quiescent cells (see Table I) . In contrast, while expression of the c-myb gene
was inducible by IL-2 in theactivated clonal population (withmaximumexpression
after 8 h of exposure to IL-2), no c-myb gene expression was observed in the quies-
cent clones even after exposure to supraoptimal concentrations ofHL-2 . This result
was consistent and reproducible even if the amount of total cellular RNA probed
was increased by up to fivefold and Northern blotswere exposed forprolonged periods
(up to 7-10 d) .
These observations suggest that the level of c-myc gene expression is most likely
not the limiting factor in regulating entry of these quiescent T lymphocytes into110
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FIGURE 2.
￿
Expression ofc-myc
and c-myb at early (day 3) and
late (day 10-12) times after an-
tigenic stimulation of T lym-
phocyte clones 14-13 (A), 11-1
(B), and 14-7 (C). At the indi-
cated day after antigenic stim-
ulation, the cells were incubated
for the indicatedamount oftime
(in hours) in 500 pM human
rIL-2, after which the RNA
was extracted and subjected to
Northern analysis .
S phase after exposure to IL-2 . The marked difference in the expression of c-myb
in response to IL-2 between early and late activated cells, however, suggested that
c-myb expression might be critical for cell cycle progression in response to IL-2 .
Correlation ofIL-2/IL-2-R-dependent Expression ofc-mycandc-mybmRNA with IL-2-de-
pendent Proliferation . If c-myb plays a central role in regulating the responsiveness
ofT cells to the IL-2-proliferative stimulus, then the kinetics of c-myb expression
in the clones should directly parallel the time course of responsiveness of the cells
to IL-2 . To examine the relationship between the IL-2-dependent proliferative ca-
pacity ofthe clones and the IL-2-dependent expression of thec-myb gene, theexpres-
sion of c-myb (along with the c-myc gene) was examined at various times after anti-loo
eo
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FIGURE 3.
￿
Kinetics of IL-2-dependent
expression of the proto-oncogenes c-myb
andc-myc and IL-2-dependent prolifera-
tion with time after antigenic stimulation
ofTlymphocyte clones 11-1 (A), 14-13 (B),
and 14-7 (C). The T lymphocyte clones
were subcultured in 50 pM humanrIL-2
at day 2 after antigenic stimulation and
every 2 dthereafter. 24 hafter subculturing
in fresh IL-2, total RNAwasextracted and
examined for c-myc (x)andc-myb (O) ex-
pression by Northern blotting. Thebands
were quantitated by densitometry. Simul-
3 5 7 9
￿
3 5 7 9 ft 13 3 5 7 9 tt 13
￿
taneously, the level of IL-2-dependent
Day After stimletion
￿
proliferation was measured by standard
proliferation assay (*). Theexpression of
theMHCclass Igene Kd was included as
a control W.
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genic stimulation under conditions of maximum IL-2 availability. To this end the
clones were freshly subcultured in saturating concentrations of IL-2 at 2-d intervals
for a period of 9-13 d starting at day 2 after antigenic stimulation. The expression
of c-myc and c-myb mRNA and cellular proliferation were then assessed 24 h after
subculture. As shown in Fig. 3, the level of c-myc over this time period was variable
but was never <60-70% of the maximum (day 3) level. IL-2-dependent c-myb ex-
pression, on the other hand, decayed dramatically with time, directly parallel with
the fall in IL-2-dependent cellular proliferation of the clones.
Cell CycleProgression Is Blockedby an Antisense Oligodeoxynucleotide to c-mybmRNA.
￿
The
close correlation between c-myb expression and IL-2-dependent cellular prolifera-
tion supports the view that this gene is critical fortheIL-2-dependent cell cycleprogres-
sion in T lymphocytes. These data are also consistent with an alternate interpreta-
tion, i.e., that c-mybgene expression is merely aconsequenceofcellular proliferation
or the state of activation of thecell but is notdirectly required forcell cycle progres-
sion in response to IL-2 . To directly assess the need for c-myb in movement of the
cellsinto S phase, we examined the effect ofan antisenseoligodeoxynucleotide com-
plementary to the 5' region of c-myb mRNA on the proliferative response ofT-lym-
phocyte clones to IL-2 .
As shown in Table II, for clone 14-13, the c-myb antisense oligodeoxynucleotide
TABLE II
Inhibition of Proliferation by Oligonucleotides Complementary to
the 5' Region of mRNA for c-myb and c-myc
Exp.
￿
PBS
￿
Antisense c-myb
￿
Antisense c-myc
￿
c-myb nonsense
1
￿
69,858 t 4,364' 15,974 t
￿
1,720 (77 .1 %)$ 23,534 t 679 (65.1 %)
￿
67,437 t
￿
1,465 (3.5%)
2
￿
98,009 t 5,046
￿
18,457 t 588 (81 .2%)
￿
27,288 t 2,380 (64.1%)
￿
76,001 t 3,063 (22 .5%)
Clone 14-13 6 d after antigenic stimulation was treated as described in Materials and Methods .
Values are the mean cpm t SEM from triplicate cultures after a 6-h pulse with 1 pCi [3H]TdR/well.
t Numbers in parentheses are percent inhibition based on the amount of proliferation seen with pretreat-
ment with PBS alone.11 2
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at a concentration of 30 AM inhibited IL-2-dependent [3H]TdR incorporation by
up to 77%. An oligodeoxynucleotide containing the 15 c-myb antisense bases, but
arranged in a random order (nonsense oligodeoxynucleotide), gave no significant
inhibition of proliferation. In dose-response studies (not shown), antisense c-myb
concentrations as low as 2.5 AM inhibited [3H]TdR incorporation by up to 40%
with no inhibition by the nonsense oligodeoxynucleotide at this concentration. Max-
imum inhibition was observed at antisense oligodeoxynucleotide concentrations
ranging from 10 to 50 A.M . Antisenseoligodeoxynucleotides to the 5' region ofc-myc
mRNA also inhibited IL-2-dependent proliferation (upto 65%), indicating that c-myc
expression is also necessary forcell cycle progression in these cells. This is in agree-
ment with results reported forhumanT lymphocytes(14, 15). Antisense oligodeoxy-
nucleotides complementary to other constitutive cellular genes, e.g., antisense R2-
microglobulin, failed to inhibit proliferation (not shown). Our observations support
the view that c-myb gene expression is not merely coincidental with cellular prolifer-
ation but is a necessary element for proliferation in these T lymphocyte clones.
Induction ofc-myb Via the TCR.
￿
The above data argue for a direct link between
c-myb gene expression as a result of the IL-2/IL-2-R interaction and movement of
T cells into S phase. However, the expression of c-myb became progressively refrac-
tory to induction via the IL-2-R, so that by day 8-10 after antigenic stimulation,
little or no c-myb expression wasdemonstrable in response to IL-2. Since these clones
can be activated and rendered sensitive to IL-2 by antigenic stimulation (10), en-
gagement of the TCR would appear to be essential for IL-2-dependent c-myb gene
expression. However, engagement oftheTCRalonehasbeen reported to be sufficient
for the induction of certain nuclear proto-oncogenes, e.g., c-myc (24). It was there-
fore possible that antigen receptor engagement could as well lead to c-myb induction
in quiescent T cells. To test this possibility we directly stimulated theTCR on quies-
cent clones using the anti-V08-specific mAb F23.1 immobilized on tissue culture
plates (16). As Table III shows, stimulation of quiescent cells with antibody in the
presence of exogenous IL-2 induces a vigorous proliferative response. Fig. 4 shows
an analysis of the kinetics of c-myb and c-myc induction after exposure of clone 14-13
to the immobilized mAb F23.1 alone. As previously reported (24), the proto-oncogene
c-mycis efficiently inducedwithin 4 h ofengagement of the TCR. Induction ofc-myc
is not dependent on IL-2-R engagement and is demonstrable in theabsenceof exog-
TABLE III
Induction of Proliferation by Anti-TCR niAb F23.1
[3H]TdR incorporation'
Day after
￿
Secondary antibody
stimulation
￿
Media
￿
Secondary antibody
￿
plus F23
3
￿
483 ± 30
￿
277 ± 35
￿
40,697 ± 400
4
￿
355 ± 22
￿
206 ± 20
￿
18,810 ± 550
96-well plates were left untreated, treated with secondary antibody alone, or
with secondary antibody and mAb F23.1 as in Materials and Methods. After
washing off unbound F23 .1, 104 cells/well were cultured in the presence of
10% supernatant from Con A-stimulated rat splenocytes as a source of IL-2
and pulsed for 6 h with 1 ttCi [ ;H]TdR. Shown is the peak of proliferation
over a 5-d period.CHURILLA ET AL .
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FIGURE 4 .
￿
Kinetics of c-myc and c-myb expres-
sion after stimulation of clone 14-13 with anti-
TCR mAb F23 .1 . Quiescent cells (day 10 after
stimulation) were stimulated with immobilized
F23 .1 antibody and incubated in culture medium
without added IL-2 for 6-8 h at 37°C . At the in-
dicated time after stimulation with F23 .1, total
RNA was extracted and Northern analysis per-
formed. Expression of the MHC Kd gene is in-
cluded as a control .
enous IL-2 . Surprisingly, c-myb was also induced byTCR engagement, even in the
absence ofadded IL-2 . Northern analysis witha probe tomouse IL-2 demonstrated
no detectable IL-2 transcript in the class I CTL clone over this time period (not
shown) . It thus seems unlikely that the induction of c-myb was due to endogenously
produced IL-2 derived from the clone .
In conjunction with this analysiswe also determined whetherde novo protein syn-
thesis was a prerequisite forc-myb induction . To this end, clone 14-13 was stimulated
with immobilized F23.1 antibody in the presence of the protein synthesis inhibitor
cycloheximide. As shown in Fig . 5, c-myb was efficiently induced byTCR engage-
ment aloneunder conditions of99% inhibition ofprotein synthesis . The induction
of c-myb in the presence of the protein synthesis inhibitor further supports the hy-
pothesis that theinduction ofc-myb does not require de novo synthesisof regulatory
molecules, e.g ., endogenous lymphokines, and implies that the induction signal is
transduced via a preformed regulatory molecule.
2-Aminopurine (2-AP)' Inhibits c-myb Induction Via the IL-2-R Pathway but not the TCR
I Abbreviation used in this paper: 2-AP, 2-aminopurine.114
￿
C-myb AND T CELL PROLIFERATION
FIGURE 5 .
￿
Induction of the proto-oncogenes
c-myc and c-myb in the presence ofthe protein syn-
thesis inhibitor cycloheximide . Clone 14-13 (day
10 after stimulation) was pretreated with cyclo-
heximide (CHX, 40,ug/ml) for 30 min and then
cultured in IL-2-free medium in control plates
or F23.1 antibody-coated plates . After the 7-h in-
cubation, total RNAwas extractedand c-myc and
c-mybRNA levels were determined by Northern
analysis .
Pathway.
￿
The above observations suggest that c-myb can be directly induced via en-
gagement of the TCR and, therefore, that an IL-2-independent pathway exists for
the induction of c-myb. It was of interest to determine whetherthe induction of this
gene by the TCR and the IL-2-R occurs by a similar mechanism, e.g., a common
intermediate .
The antimetabolite 2-AP has been shown to inhibit c-myc expression in fibroblast
cells undergoing serum-stimulated proliferation (26), presumably due to its ability
to inhibit selected cellular protein kinases . In view of the effect of 2-AP on nuclear
proto-oncogene expression in serum-stimulated cellular proliferation, it was of in-
terest to determinewhetherthe drug influences the induction of thec-mycand c-myb
proto-oncogenes after engagement of the IL-2-R by IL-2 in activated T cells (day
3 after stimulation) . As shown in Fig . 6, 2-AP markedly inhibited IL-2-driven ex-
pression of both c-myc and c-myb in the activated T lymphocyte clone, indicating
that the IL-2/IL-2-R-mediated pathway of c-myc and c-myb induction was sensitive
to this inhibition .
A different result emerged when we assessed the effect of2-AP on c-myc and c-myb
induction mediated by engagement of theTCR. As shown in Fig . 7, 2-AP inhibits
expression of c-myc induced by engagement of the TCR, while in marked contrast,
c-myb expression is enhanced . It appears that 2-AP has adifferential effect on c-myb
and c-myc induction afterTCR engagement but inhibits the IL-2-induced expres-CHURILLA ET AL.
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FIGURE 6 .
￿
The effect of 2-AP
on the IL-2-dependent induction
of c-myb and c-myc in activated
T lymphocytes . Clone 14-13
(day 3 after antigenic stimula-
tion) was incubated for 7 h in
medium supplemented with 10
mM 2-AP alone or 2-AP in
combination with 500pM hu-
man rIL-2 . Total RNAwas then
extracted and examined by
Northern analysis for the ex-
pression of c-myc and c-myb
mRNA .
sion of both these proto-oncogenes . Importantly, 2-AP appeared to have no effect
on the expression of other genes, e.g ., MHC class I (see Fig. 6) constitutively ex-
pressed in these cells .
Discussion
Most previous studies on the role of c-myb and c-mycexpression inTlymphocytes
have centered on the use of either lectin-stimulated heterogeneous populations of
cells (24, 25) or on cell lines or clones that are IL-2 dependent and antigen indepen-
dent (27) . In our studies, we examine the regulation of MHC-restricted, antigen-
specific murine T lymphocyte clones . Utilization of these cells enables us to directly
assess the mechanisms underlying the control of proliferation in cells that require
routine restimulation with antigen (every 7-14 d) for their propagation in culture .
The aim of this investigation was to determine whether responsiveness ofT lym-
phocytes to the proliferative stimulus mediated by IL-2 is linked to the expression
of particular proto-oncogene(s) . We found that in activated T lymphocyte clones
capable of proliferating in response to exogenous IL-2, the c-myb proto-oncogene11 6
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FIGURE 7 .
￿
The effect of 2-AP
on TCR-mediated induction of
c-myband c-myc . Quiescent (day
11) clone 14-13 cells were stimu-
lated with F23.1 antibody in the
presence of 10 mM 2-AP or
were incubated in 2-AP sup-
plementedmedium alone as de-
scribed in Table III . TotalRNA
was extractedandexaminedby
Northern analysis for the ex-
pression of c-myc and c-myb
mRNA .
was readily induced by the IL-2/IL-2-R interaction . We also found that quiescent
T lymphocyte clones that did not respond to the proliferative stimulus of IL-2 failed
to express detectable levels of c-mybmRNA after exposure to IL-2 . These data im-
plicated c-myb as a possible regulator of IL-2-dependent T lymphocyte prolifera-
tion .A role for c-myb was further supported by the finding of a close temporal corre-
spondence between the extent ofDNA synthesis in response to IL-2 and the level
of c-myb RNA expression in T lymphocytes transiting from an activated phase to
a quiescent phase as a function of time after antigenic stimulation . Finally, the im-
portance of c-myb in regulating movement of T lymphocytes into the S phase of
the cell cycle was directly demonstrated by specific inhibition of IL-2-driven DNA
synthesis by treatment ofcells with an antisense c-myboligodeoxynucleotide . Overall,
these data provide strong support for the view that c-myb expression is necessary
for IL-2-dependentT lymphocyte proliferation, and that the lack of IL-2-induced
expression of this proto-oncogene in quiescentT lymphocytes accounts in part for
the unresponsiveness of quiescent T lymphocytes to the IL-2-proliferative signal .
That c-myb expression is necessary but not sufficient for IL-2-drivenT lympho-
cyte proliferation is evident from the effect ofthe antisense c-myc oligodeoxynucleo-
tide that also markedly inhibited proliferation . In contrast to c-myb, the expression
of the c-myc proto-oncogene is inducible by IL-2 even in quiescent cells . While its
expression is obviously not sufficient for IL-2-dependent proliferation, c-myc, how-CHURILLA ET AL.
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ever, appears necessary for movement into the S phase of the cell cycle. A role for
c-myc in lymphocyte activation/proliferation has been demonstrated in studies with
human (14, 15, 24) and murine (27) T lymphocytes. Our data showing inhibition
oflymphocyte proliferation by antisense c-myc oligodeoxynucleotide are consistent
with these data.
In this report we show that c-myb expression is inducible either by engagement
of the T lymphocyte antigen receptor or by engagement of the IL-2-R. Upregula-
tion of c-myb expression in T lymphocytes as a result of IL-2-R engagement has
been previously reported (25) and a direct dependence of c-myb expression on the
IL-2/IL-2-R interaction hasbeen suggested (25, 28). Ourresultsare consistent with
this notion in that engagement of the IL-2-R on activated T lymphocytes causes
a much greater increase in c-myb expression than results from TCR engagement
(A. Churilla, unpublishedobservations). C-myb expression is also stimulated via the
TCR anditsinduction does not requirede novo protein synthesis in the Tcell. Thus,
the TCRdependent induction of c-myb can not be accounted for by generation of
acytokine, e.g., IL-2, in the T cell, which could then stimulate viathe IL-2-R. Also,
c-myb induction by the IL-2-R pathway is sensitive to 2-AP while the drug actually
serves to increase the level ofc-mybRNA inducedby TCR engagement. These results
suggest that the mechanisms of c-myb induction after TCR and IL-2-R engagement
most likely are different.
In view of the capacity of signals from either the TCR or the IL-2-R to induce
c-myb, it is likely that under usual conditions of T cell activation c-myb expression
is biphasic with an initial burst of c-myb transcription as a result of antigen receptor
engagement followed by upregulation of c-myb as a result of IL-2-R engagement.
The IL-2-Blinked c-myb inductionis most closely associated with cell cycle progres-
sion and cellular proliferation. The significance of antigen receptor-induced c-myb
expression is less clear. It is noteworthy, however, that quiescent CD8+ T cell clones
triggered via the antigen receptor alone appear to be able to synthesize DNA but
not progress completely throughthecell cycle and undergo proliferation (T J. Braciale,
unpublished observations). C-myb itself may, therefore, have both competence and
progression functions depending on the state of activation of the cells.
Recent evidence (29, 30) indicates that the IL-2-R can transduce a proliferative
signal by a pathway that does not require protein kinase C, whereas TCRmediated
signaling events maybe proteinkinase C dependent. These findings, like those reported
herein, reinforcethe notion that intracellular signalingviathese tworeceptor systems
are by different mechanisms.
Our finding of inhibition of IL-2-induced c-myb expression by the protein kinase
inhibitor 2-AP appears to be at variance with the evidence for IL-2 signaling by
a protein kinase C-independent pathway. It should be noted, however, that the in-
hibitory effect of 2-AP appears to be specific for certain classes of protein kinases,
e.g., heme-regulated protein kinases (26), and that no direct effect of the 2-AP on
protein kinase C has been documented. Since the mechanism of action of 2-AP is
not precisely known, the drug may affect multiple sites along the IL-2-signaling
pathway. Our observations at least raise the possibility that a protein kinase-medi-
ated phosphorylation event is critical for IL-2-dependent c-myb induction and sub-
sequent proliferation.
A number of different mechanisms of regulation of proto-oncogene expression118
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have been proposed (31-33). Perhaps the simplest hypothesis to account forourfindings
is that a preformed regulatory factor presentin quiescent Tlymphocytes is modified
(e.g., phosphorylated or dephosphorylated) as a result of TCR engagement. This
"competence" (modified regulatory) factor canthen promoteexpression ofc-myb directly
at a low level and would be susceptible to further alteration promulgated as a result
of signaling through the IL-2-R. This second modification mediated through the
IL-2-R pathway would then allow this further modified or "progression" factor to
induce c-myb expression with a higher efficiency. Most importantly, while the un-
modified form of this regulator would be present in the quiescent cells (and possibly
in activated cells), the two modified forms of this regulator must be limiting, i.e.,
transiently present in activated cells and absent in quiescent cells, in order to ac-
count forthetime-dependent decay in sensitivity oftheT cells to theIL-2 -proliferative
stimulus (Fig. 3). Models involvingde novo expression ofIL-2-dependent c-myb regu-
lators after TCR engagement likewise can account for these results. These models
are highly speculative at present but suggest avenues forfurther studies on the regu-
lation of T lymphocyte growth.
T lymphocyte activation/proliferation is regulated at severallevels. The availability
of antigen in a form capable of engaging the TCR represents the primary or most
basic form of regulation. With the evolution of knowledge concerning lymphocyte-
specific growth factors, it has become clear that the availability of IL-2 and related
lymphocyte-specific growth factors as well as the cell surface expression of the rele-
vant hormone receptorsrepresents anotherlayer ofregulation oflymphocyte growth.
In this report we have obtained evidence for a third, intracellular level of regulation
where expression of genes critical for lymphocyte growth, e.g., c-myb, is controlled
not only at the level of growth factor receptor engagement but also at the level of
intracellular modulators of gene expression. Our finding provides a framework for
further analysis of the molecular basis of lymphocyte quiescence and also may offer
new avenues of investigation for understanding the pathogenesis of disorders such
as angioimmunoblastic lymphadenopathy (34) andtheautoimmune diseases associated
with the homozygous lpr/lpr phenotype in mice where aberrant proto-oncogene ex-
pression is linked to abnormal lymphocyte proliferation (35, 36).
Summary
We previously reported that with time, after antigenic stimulation of antigen-
regulated murine Tlymphocyte clones, total IL-2-R expression decayed 10-50-fold,
commensurate with a decline in the ability of the cells to proliferate to IL-2 . How-
ever, late after antigenic stimulation, when the cells were refractory to the IL-2-
proliferative stimulus, high levels of high affinity IL-2-R remained.
In this report we furtherexplore thebasisofunresponsiveness to IL-2 in thequiescent
clones. We show that the proto-oncogene c-myc is induced in the late cell population
by IL-2 to comparable levels observed early afterantigenstimulation. IL-2-dependent
c-myb induction, however, is seen only earlyafteractivation butnotin the late-activated
population. Analysis of the IL-2-dependent expression of c-myb mRNA with time
after antigenic stimulation showed that steadystate c-myb expression declines dra-
matically with kinetics closely paralleling a decay in IL-2-dependent proliferative
ability. In contrast, steadystate c-mycexpression remainshigh throughout this period.
Expression ofc-myb is critical for proliferation ofthesecellssince antisenseoligodeoxy-CHURILLA ET AL.
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nucleotide to c-myb can inhibit their IL-2-dependent proliferation. We present
evidence for a pathway of c-myb induction via the TCR that is independent of the
IL-2/IL-2-R interaction. In addition, the inhibition of IL-2-R-induced c-myb ex-
pression by 2-aminopurine and enhanced induction of c-myb via the TCR demon-
strate that TCR activation and IL-2-R activation lead to induction ofc-myb by different
mechanisms.
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